UNSPSC 51263310: Penirolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BT9Y6D2DR0. European Medicines Agency schedules Penirolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09670MIG. Penirolol generally arises in the molecular formula C15H22N2O2. The term PENIROLOL is an International Non-Proprietary Name or INN. PENIROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule penirolol under HS 29269095 and SITC 51484. As of Q4 2014, PENIROLOL remains the US FDA Preferred Term for this commodity. Penirolol bears US NLM identifiers UMLS ID C1882314 and NCI Concept Code C66339. SMILES: OC(CNC(CC)(C)C)COC1C(CCCC1)C#N.

UNSPSC 51263310 Penirolol is a Commodity code that represents pharmaceutical products, though recent state and local solicitations tagged under it show activity in naloxone procurement and pharmacy benefit management initiatives rather than penirolol specifically. Seminole County, Florida recently posted an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to support community health initiatives. The Texas Health and Human Services Commission issued a Request for Information to explore direct-to-manufacturer prescription programs and vendor capabilities for therapeutic pharmacy initiatives. State and local bodies issuing under this code span county health departments and state health agencies, reflecting procurement interest in pharmaceutical supply chains and pharmacy benefit program innovation.

Activity is concentrated in Florida and Texas based on recent postings. The Seminole County naloxone IFB (IFB60459723LAS) closed July 26, 2023, with a two-year initial term and one-year renewal option, requiring vendors to submit unit costs, maintain workers' compensation and liability insurance, and comply with E-Verify and drug-free workplace certification. The Texas HHS Commission RFI (HHS0017013) posted April 3, 2026, sought vendor information on direct contracting between state pharmacy programs and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal evaluation timeline or award value specified at the information-gathering stage. Neither solicitation designated set-aside preferences for disadvantaged enterprises.